BridgeBio Pharma BBIO Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's net change in cash?
- BridgeBio Pharma (BBIO) reported net change in cash of $309.88M in Q1 2026.
- How has BridgeBio Pharma's net change in cash changed year-over-year?
- BridgeBio Pharma's net change in cash increased by 320.6% year-over-year, from -$140.5M to $309.88M.
- What does net change in cash mean?
- The total change in the company's cash balance over the period.
- How do you interpret net change in cash?
- A positive change indicates cash accumulation, while a negative change indicates cash depletion, which is common for R&D-heavy biotech firms.
- How does net change in cash compare across companies?
- Critical for assessing runway in pre-revenue or early-stage commercial companies.